Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients Source: Eur Respir J, 52 (2) 1701190; 10.1183/13993003.01190-2017 Year: 2018
Pneumonia caused by extensive drug-resistant Acinetobacter baumannii among hospitalized patients: genetic relationships, risk factors and mortality Source: International Congress 2017 – Respiratory infections in critically ill and immuno-depressed patientes Year: 2017
Clinical outcomes of the patients with multidrug-resistant Acinetobacter baumannii pneumonia in critical care setting: A retrospective cohort study in Taiwan Source: International Congress 2018 – Preclinical and clinical studies of critical illness Year: 2018
Predictive factors for multidrug-resistant pathogens in hemodialysis patients with pneumonia : a multicenter study Source: International Congress 2017 – CAP: severity scores, risk groups and biomarkers Year: 2017
Early mortality in patients with community-acquired pneumonia: causes and risk factors Source: Eur Respir J 2008; 32: 733-739 Year: 2008
The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis Source: Eur Respir J, 51 (2) 1701953; 10.1183/13993003.01953-2017 Year: 2018
Incidence, characteristics and outcomes of patients with severe community acquired-MRSA pneumonia Source: Eur Respir J 2009; 34: 1148-1158 Year: 2009
Clinical characteristics and prognostic factors of patients with Stenotrophomonas maltophilia pneumonia: 10 years experience of single center Source: International Congress 2019 – Airway infection in COPD Year: 2019
Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors Source: Eur Respir J 2010; 35: 598-615 Year: 2010
Pseudomonas aeruginosa isolates in bronchiectasis: Wath particulaties and risk factors? Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016
Epidemiology, treatment and outcomes of nosocomial pneumonia due to Gram-negative bacteria Source: Eur Respir J 2007; 30: Suppl. 51, 408s Year: 2007
Clinical and microbiological characteristics of Pseudomonas aeruginosa isolates from patients with COPD Source: Eur Respir J 2005; 26: Suppl. 49, 58s Year: 2005
Risk factors for multidrug resistant bacteria in Hospital-Acquired Pneumonia: A three-year cohort study Source: Annual Congress 2010 - Unusual pathogens in respiratory infections Year: 2010
Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis Source: Eur Respir J 2015; 45: 1353-1363 Year: 2015
Community acquired legionella pneumophila pneumonia, clinical characteristics, outcomes and prognostic factors Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants Year: 2015
An experience of moxifloxacin (MOX) use in therapy of nosocomial pneumonia (NP) in patients who hadn‘t risk factors to be infected by Pseudomonas aeruginosa Source: Eur Respir J 2005; 26: Suppl. 49, 187s Year: 2005
A prospective controlled study of azithromycin on lower respiratory tract infections caused by multi-drug resistant Pseudomonas aeruginosa in the elderly in intensive care unit Source: Eur Respir J 2005; 26: Suppl. 49, 187s Year: 2005
New evidence of risk factors for community-acquired pneumonia: a population-based study Source: Eur Respir J 2008; 31: 1274-1284 Year: 2008
Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia: a cohort study Source: Eur Respir J, 54 (1) 1900057; 10.1183/13993003.00057-2019 Year: 2019
Predicting the outcome of respiratory Pseudomonas aeruginosa infection in vivo Source: International Congress 2017 – Cystic fibrosis: treatments and monitoring Year: 2017